Carmelo LUCI

Dr. Carmelo LUCI

Centre Méditerranéen de Médecine Moléculaire (C3M), Université Côte D’Azur, INSERM, 06204 Nice, France
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2008 in Nature Immunology
Verified
Journal Article
Closed access
Carmelo LUCICarmelo LUCI
Carmelo LUCI
ARAna Reynders
Ana Reynders
IIIvaylo I Ivanov
Ivaylo I Ivanov
CCCeline Cognet
Celine Cognet
LCLaurent Chiche
Laurent Chiche
ETElena Tomasello
Elena Tomasello

30 October 2007 in Immunological Reviews
Verified
Journal Article
Closed access
CGClaude Grégoire
Claude Grégoire
LCLionel Chasson
Lionel Chasson
Carmelo LUCICarmelo LUCI
Carmelo LUCI
ETElena Tomasello
Elena Tomasello
FGFrédéric Geissmann
Frédéric Geissmann
TWThierry Walzer
Thierry Walzer

16 May 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
Meri K. TulicMeri K. Tulic
Meri K. Tulic
ECElisa Cavazza
Elisa Cavazza
YCYann Cheli
Yann Cheli
Arnaud JacquelArnaud Jacquel
Arnaud Jacquel
Carmelo LUCICarmelo LUCI
Carmelo LUCI
TPThierry PASSERON
Thierry PASSERON
T-cells play a crucial role in progression of autoimmunity, including vitiligo, yet the initial steps triggering their activation and tissue damage remain unknown. Here we demonstrate increased presence of type-1 innate lymphoid cells (NK and ILC1)-producing interferon gamma (IFNγ) in the blood and in non-lesional skin of vitiligo patients. Melanocytes of vitiligo patients have strong basal expression of chemokine-receptor-3 (CXCR3) isoform B which is directly regulated by IFNγ. CXCR3B activation by CXCL10 at the surface of cultured human melanocytes induces their apoptosis. The remaining melanocytes, activated by the IFNγ production, express co-stimulatory markers which trigger T-cell proliferation and subsequent anti-melanocytic immunity. Inhibiting the CXCR3B activation prevents this apoptosis and the further activation of T cells. Our results emphasize the key role of CXCR3B in apoptosis of melanocytes and identify CXCR3B as a potential target to prevent and to treat vitiligo by acting at the early stages of melanocyte destruction.

1 December 2007 in Vaccine
Verified
Journal Article
Closed access
NÇNicolas Çuburu
Nicolas Çuburu
MKMi-Na Kweon
Mi-Na Kweon
JSJoo-Hye Song
Joo-Hye Song
CHCatherine Hervouet
Catherine Hervouet
Carmelo LUCICarmelo LUCI
Carmelo LUCI
CCCecil Czerkinsky
Cecil Czerkinsky

1 August 2017 in Journal of Hepatology
Verified
Journal Article
Closed access
SPStéphanie Patouraux
Stéphanie Patouraux
DRDéborah Rousseau
Déborah Rousseau
SBStéphanie Bonnafous
Stéphanie Bonnafous
CLCynthia Lebeaupin
Cynthia Lebeaupin
Carmelo LUCICarmelo LUCI
Carmelo LUCI
PGPhilippe Gual
Philippe Gual

19 February 2018 in Hepatology
Verified
Journal Article
Closed access
PDF file
CLCynthia Lebeaupin
Cynthia Lebeaupin
DVDéborah Vallée
Déborah Vallée
DRDéborah Rousseau
Déborah Rousseau
SPStéphanie Patouraux
Stéphanie Patouraux
SBStéphanie Bonnafous
Stéphanie Bonnafous
BBBéatrice Bailly‐Maitre
Béatrice Bailly‐Maitre